Lorediplon meets in Phase II insomnia trial

In February, Ergomed plc (LSE:ERGO) said 5 and 10 mg oral lorediplon each met the primary endpoint in a Phase II trial to treat insomnia. Specifically, low-

Read the full 271 word article

User Sign In